Context Thyroid hormones (TH) are essential for brain development and function. The 2 TH transporters monocarboxylate transporter 8 (MCT8) and organic anion transporter1 3 C1 (OATP1C1) facilitate the transport of TH across the blood-brain-barrier and into 4 glia and neuronal cells in the brain. Loss of MCT8 function causes Allan-Herndon-5 Dudley syndrome (AHDS, OMIM 300523) characterized by severe intellectual and 6 motor disability due to cerebral hypothyroidism. We describe the first patient with loss 7 of OATP1C1 function. The patient was a 15.5-year-old girl with normal development 8 in the first year of life, who gradually developed dementia with spasticity and 9 intolerance to cold. Brain imaging demonstrated grey and white matter degeneration 10 and severe glucose hypometabolism. 11 Methods We performed exome sequencing of the patient and parents to identify the 12 disease-causing mutation and studied the effect of the mutation through a panel of in 13 vitro experiments, including T4 uptake studies, immunoblotting, and 14
Introduction
Thyroid hormone, common name for the pro-hormone thyroxine (T4) and its active 2 form triiodothyronine (T3), is critical for brain development and functioning, 3 underscored by the devastating consequences of congenital hypothyroidism (1) . 4 Important steps leading to TH action in the brain include transport of T4 across the 5 blood-brain barrier, uptake of T4 by astrocytes, conversion to T3 by type 2 deiodinase 6 (DIO2), and supply of T3 to target cells such as oligodendrocytes and neurons (2-4). 7 By binding to nuclear T3 receptors in these cells, T3 initiates powerful genetic control 8 on myelination (5) and neuronal differentiation in various brain regions (6). In the 9 human brain, T4 transport across the blood-brain barrier is predominantly mediated by 10 monocarboxylate transporter 8 (MCT8, encoded by SLC16A2; OMIM 300095), while 11 T4 uptake by astrocytes is facilitated by organic anion transporting polypeptide 1C1 12 (OATP1C1 encoded by SLCO1C1; OMIM 613389) (7). MCT8 deficiency in humans 13 causes intellectual disability, dystonia, spasticity and hypomyelination due to a 14 hypothyroid state in the brain (Allan-Herndon-Dudley syndrome, OMIM 300523), and 15 is associated with low serum T4 and high T3 levels resulting in a hyperthyroid state in 16 peripheral tissues (8, 9) . Until now, patients with OATP1C1 defects have not been 17 reported. We here describe such a patient showing features of brain hypothyroidism. The patient was a 15.5-year-old girl, born to healthy parents in a rural area in Norway. 22 Her two younger sisters were healthy. Birth measurements were normal. Eye contact 23 was achieved at an early age and development was unremarkable in the first months. 24 Although she walked independently at 10 months, the mother had an impression that 25 "something was wrong". In the toddler age, movements were clumsy and vocal sounds 1 and language seemed to develop unexpectedly slow. Between 2 and 3 years, she 2 appeared aggressive with stereotypic behaviour and was considered to be autistic. 3 Intellectual disability was suspected by the local health service at 4 years. Psychomotor 4 functioning was best between 5 and 6 years, when she spoke in two-or three-word 5 sentences, ate independently, was continent, could walk, and jumped on a trampoline. 6 Due to suspected loss of skills she was referred to our hospital at 9.5 years. Despite 7 extensive work up, no diagnosis was made. She started to lose expressive verbal 8 language and gradually lost cognitive and motor functioning ( Table 1 and Figure 1A) . 9 In addition, body weight and height development stunted and declined to the 2.5 th 10 percentile, prompting the placement of a percutaneous gastrointestinal feeding tube at 11 the age of 11 years. At 13 years, she was demented and incontinent for bowel and 12 bladder functioning. Later, urinary retention required daily bladder catheterization. She 13 had no expressive verbal language, and walking was impaired due to gait apraxia, Ethical considerations 22 The current study was formally approved by the Regional Committees for Medical Expression constructs, cell culture and transfection 1 The cloning of human OATP1C1 cDNA into pcDNA3.1 and human CRYM cDNA into 2 pSG5 has been previously described (15,16). OATP1C1 cDNA was subcloned into 3 pSG5 with addition of a C-terminal V5 tag (further referred to as wild-type OATP1C1-4 V5) which did not affect T4 transport function (data available upon request). The Functional studies confirmed loss of T4 transport function in mutated OATP1C1 25 In order to study if the identified mutation impairs OATP1C1 function, we performed 1 complementary in vitro studies. To allow immunochemical detection, expression 2 constructs were made of wild-type OATP1C1 and the Asp252Asn mutant equipped 3 with a C-terminal V5 epitope. Since Asn residues may undergo hydrolysis to Asp (21), 4 the native residue in OATP1C1, we also introduced the Asp252Ala mutation. The effect 5 of both mutations on T4 transport by OATP1C1 was evaluated in transiently transfected 6 JEG-3 cells. Compared to wild-type OATP1C1, T4 uptake was diminished by 70% by 7 the patient mutation and nearly completely inhibited by the artificial Ala mutation 8 ( Figure 2A ). We evaluated the impact of both mutations on OATP1C1 protein 9 expression levels by immunoblotting on total lysates of JEG-3 cells transfected with 10 wild-type or mutant OATP1C1. For wild-type OATP1C1-V5, bands were detected at 11 ~75 kDa, representing the mature, glycosylated protein (22), and at ~50 kDa, most 12 likely representing its immature form ( Figure 2B ), as has been described for OATP2B1 13 (23). The Asp252Asn mutation predominantly reduced the abundance of the mature 14 protein, whereas the Asp252Ala mutation resulted in a marked reduction of both 15 proteins ( Figure 2B ). Cell surface protein expression determined by surface 16 biotinylation analyses showed that both OATP1C1 mutants were markedly reduced in 17 the cell membrane fraction compared to mature wild-type OATP1C1 ( Figure 2C ). This 18 corresponded with the predominant peri-nuclear localization of both mutants as 19 revealed by immunocytochemistry ( Figure 2D ). Similar results were obtained in COS-20 1 cells (data not shown). These findings suggested that both Asp252 mutations affect 21 OATP1C1 protein maturation, stability and intracellular trafficking. To substantiate 22 this hypothesis, we generated an OATP1C1 structure homology model based on the 23 crystal structure of E. coli multidrug transporter MdfA (PDB#4ZP0) ( Figure 2E ).
24
Molecular dynamic simulations suggested that Asp252 forms hydrogen bonds with 25 Lys248, both predicted to be located at the extracellular end of transmembrane domain After 6 weeks she resumed eye contact and became more alert ( Table 1 ). Her general 8 condition and quality of life improved. Importantly, the startle response episodes were 9 markedly reduced in number and severity. Painful muscle spasms almost disappeared, 10 she could swallow her own tablets and much of her own food, and urinary retention 11 causing the need for bladder catheterization became rare. After the treatment with Triac 12 was started, there was no further decrease in postural ability, and in fact in two postural 13 positions the level of ability increased ( Figure 1A ). However, scoliosis continued to 14 progress. Rectal temperature increased to normal values ( Figure 1D, We report for the first time a human disease associated with mutation of the brain In the brain, impaired OATP1C1 function likely reduces T4 uptake in astrocytes and 9 its subsequent conversion to T3. Thus, the reduced availability of T3 to target cells has become clear that OATP1C1 is a specific T4-transporter, which is importantly 8 expressed in human astrocytes. We hope that our report, describing a novel 9 neurodegenerative disease associated with a mutation in the T4 transporter OATP1C1, 10 will fuel further research in the field of TH transporters. Acknowledgments 21 We are grateful to the family for taking part in this study. The sequencing service was Figure 3. Thyroid hormone physiology in the brain. 1 The thyroid gland produces the pro-hormone T4 and to a lesser extent its active 2 hormone T3. In the body, the majority of T3 is produced locally by deiodination of T4.
3
The main access of thyroid hormone to the brain is across the blood-brain-barrier, 4 where MCT8 transports both T4 and T3. T4 uptake in astrocytes is mediated mainly by 5 OATP1C1. T4 in astrocytes is converted by the DIO2 deiodinase to T3, which is 6 released into the brain parenchyma by an unknown transporter. By this mechanism, 7 astrocytes supply neurons and oligodendrocytes with sufficient amounts of T3 for 8 proper neural differentiation and functioning. A defective OATP1C1 results in 9 impaired uptake of T4 in astrocytes and therefore insufficient availability of T3 in 10 neural cells. Triac, a T3 analogue with T3-like biological effect, normally excreted at 11 very low concentration, passes the blood-brain-barrier and enters brain cells through an 12 unknown transporter.
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